Chelexa BioSciences, Inc. is focused on infection prevention therapies for the skin. Our revenues and returns for our investors will come from development and commercialization of our proprietary, patent pending BioLexa™ biofilm prevention platform for human use in surgical site infections as well as acute and chronic wounds. In addition, we will partner the BioLexa platform for use in companion animals in exchange for license fees, pre-commercial milestones, royalties and commitment by the licensee to fund all development and commercialization of the products in companion animals.